Etienne Cosseau
Junior Global Brands Manager - CCS Health
- Report this post
Dear network,I'm delighted to announce that I've been Assistant Brands Manager CCS Health at Servier, in the Global Product Strategy CMVD department, for over a month now.I'd like to thank Pierre-André GERONIMI and Yasser ALASHI, MBA for the trust they've placed in me and their day-to-day support, which has enabled me to start this experience with confidence.I'm determined to use all the skills I've acquired during my training and my previous experiences to play a significant role in the CMVD team and to continue in the pharmaceutical field in the future.
44
To view or add a comment, sign in
More Relevant Posts
-
Simone Berger
Chief People Officer / Executive Board Member STADA Group
- Report this post
What's your life purpose?Together with Peter, our CEO, I spent yesterday afternoon with 10 talents from 8 different STADA countries, discussing not only career ambitions but reflecting on big dreams and life purpose. I was intrigued to learn that one colleague aspires to discover a new pharmaceutical approach to improve the health of humanity, the other aims to publish TED talks, and one shared (very honestly!) that the purpose was to achieve financial freedom. The discussion is so important because at STADA Group we look holistically at Talent Development. As part of our Growth Culture, we care first and foremost about Personal Growth and Team Growth, ultimately Organizational Growth is then just a consequence. So, what's your purpose in life? Share below the post. #caringforpeopleshealth #lifepurpose #growthmindset #talentdevelopment #onestada
371
7 Comments
Like CommentTo view or add a comment, sign in
-
STADA Group
72,767 followers
- Report this post
STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty. • Double-digit growth journey continues with 16% sales increase to €2.1bn (adj.) and 30% EBITDA to €509 million (adj.) in first six months of 2023 • Organic growth in Consumer Healthcare is largest contributor to record performance; Specialty segment with double-digit growth as well. Market-share gains in Generics • STADA CEO Peter Goldschmidt: “STADA’s purpose, values and strategy are the base for our continued double-digit growth in sales and earnings. With this momentum, we are well on track to exceed over €4 billion sales and €1 billion EBITDA this year.” Read the full press release: https://lnkd.in/ezFfvcbP#STADANews #Results
490
See AlsoDaily Themed Crossword August 13 2024 Answers (8/13/24) - Try Hard GuidesPonzi Scheme Prosecution: Justice Served: The Road to Ponzi Scheme Prosecution and Conviction - FasterCapitalJune 13, 2023 Trump pleads not guilty in historic federal indictment | CNN PoliticsJournal articles: 'Trust in literature. Law in literature. American fiction' – Grafiati8 Comments
Like CommentTo view or add a comment, sign in
-
Volker S.
EVP Global Consumer Health & eCommerce at STADA Group
- Report this post
Delighted to share our very strong H1 results driven by outperformance in all three of our segments, CHC, Generics and Speciality, delivering +16% Net Sales and +30 EBITDA (adjusted) of almost entirely organic growth and poised to exceed €4 bn in sales and €1 bn EBITDA (adj). for the year.Consumer Healthcare continues to be a key driver of growth thanks to our successful local hero brand strategy of broad brand portfolio activation fueled by successful product launches which has been delivering market share gains across countries and categories. A brand portfolio which is being strengthened further by the recently announced acquisition of several Sanofi CHC brands which is expected to close in H2.These results come together with continued investment and progress in terms of ESG & Sustainability as evidenced in an improved rating by Morningstar SustainalyticsA big thanks to our dedicated team and our many partners around the world in helping us to deliver on our Purpose: Caring for People’s Health as a Trusted Partner. #OneStadaForGrowthcheck out further details here:https://lnkd.in/e2-cVaSf
64
6 Comments
Like CommentTo view or add a comment, sign in
-
Servier Egypt
7,654 followers
- Report this post
Servier Egypt Scientific office and Servier Egypt Industries are coming together into one entity “One Servier EGYPT”.As one entity, a brighter star, we are destined to accelerate our progress, achieve our business objectives – 2B EGP milestone in 2030 – and fulfill the SERVIER 2030 vision to shine as an innovative patient-driven organization. As one entity, we are stronger, more resilient, more agile, more powerful, and proud. Each SERVIER employee, in the scientific office or in the factory, is a passionate member. Now as one entity they will together, like stars, light the universe… That's the power of unity and teamwork, the power of One Servier EGYPT.#OneServierEgypt #One2BGreat #reachingnewskies #Servier_Egypt
113
5 Comments
Like CommentTo view or add a comment, sign in
-
Gareth Armanious, PhD
- Report this post
Johan, I appreciate you sharing your experience. I enjoyed the article and some thoughts & questions came to mind while reading it.1. How far off are we on the economics of societal cost? That recent study cites €11.500 average cost per year societal cost of people who are obese and overweight, while medication cost is ~€5,200/yr currently 2. No mention of adverse effects or difficulty starting or stopping the medication.3. The observed effects are notable, particularly the changes in dietary preferences.4. The observations related to alcohol consumption are intriguing, especially considering the potential influence of GLP-1 RAs on addictive substances such as cigarettes, alcohol, opioids, and cocaine.Thanks for sharing.
8
1 Comment
Like CommentTo view or add a comment, sign in
-
Björn Öste
Co-founder of Good Idea Inc, Oatly AB, Aventure AB and Crop Tailor AB
- Report this post
Congratulations, Johan. These are important steps for your health and well-being. Happy to note that you do not seem to suffer any major side effects as clearly, many do. (40-60 percent, depending on which studies and reports you read). At least, at this point, the cost-benefit analysis is clearly in your favor. That is absolutely Awesome! Keep up the good work!I agree that we will see a fundamental change in how we eat and what we consume. No wonder the likes of Nestlé and others are very nervous right now. Cookie and junk food sales will go down. At the same time, the GLP-1 agonists open up opportunities of a lifetime for the food industry. Unless you are prepared to take Wagawoy for life, the renewed focus on weight loss and blood sugar control presents great new opportunities for the food industry. Carefully designed and clinically validated foods can for example provide a very comfortable "off-ramp" where, after a year's drug use, patients can switch over to foods that will provide continued blood sugar management and keep weight in check at a much lower cost and without risk of side effects. And also, Johan, be a bit careful with your weight loss, because it is unfortunately not only fat you are losing but also muscle mass. You may need to make sure to switch to foods, for example, rich in the right kinds of amino acids, to help restore those muscles. There is a new dawn for true Food-As-Medicine here and I'm happy to be part of that new movement and help set new standards for foods that help prevent diseases, and maybe even be part of the cure. There are now foods being developed and clinically tested that stimulate GLP-1 naturally and that promise similar results as the GLP-1 agonists offer. They will soon be available in the market and will help reach even more people at significantly lower costs and without the need for a doctor's prescription and frequent injections. Keep your eyes open. More news to come.
21
Like CommentTo view or add a comment, sign in
-
Johan Jörgensen
Founder and partner at Sweden Foodtech
- Report this post
So, after I wrote an article in AgFunder news (thanks Elaine Watson) and posted on my experiences with #wegovy the other day, Björn Öste, illustrious founder of Oatly and leading knight in the cruzade against the metabolic syndrome through his many new ventures such as Good Idea, reposted with some comments. I find them highly valid, so please read them. And some additional notes:1. Thanks for your care and comments on side-effects, Bjorn. I am happily reporting none, aside from a slight tiredness the days that I take the injections. But I was afraid before I started because many people do experience one or several side-effects. You need to be aware...2. Yes, you need to combine any intake of GLP-1 drugs with a change in food habits. You eat less so need to make sure you get the nutrition you need. If you can go a day without feeling hunger you sometimes must force yourself to eat.3. I am super, super happy about the work Bjorn is doing with curing the metabolic syndrome with real food. I think that's the best way forward. The reason for me being on Wegovy is that I needed to fix myself now. I cannot afford to wait for a better food system, filled with the products we all need. 4. This fight is not Pharma against Food or Farmers. It is Pharma, Farmers and real food against a broken, corrupt and predatory food system. 5. The food system can be easily fixed. But the current players might not be able to retain their privileges, and the politicians in their pockets (or the just ignorant ones) might have to look for new careers. So, it's going to be the usual issue of power and greed that decides what we eat for still some time.6. Probably the market will solve it for us. When Bjorn and the next gen GLP-1 drugs start making inroads for real we need to understand that certain parts of the food sector will literally lose hundreds of millions of their very best customers. That won't go unnoticed by either investors, shareholders or accountants. Watch this space - it's heating up massively. Do remember to divest from your soon-to-be stranded assets.
10
1 Comment
Like CommentTo view or add a comment, sign in
-
Pharmacy24® Canada
40 followers
- Report this post
It's the last month of school! Complete our summer vacation crossword! Tell us how many you got in the comments below!#PharmaChoice #Pharmacy #PharmaChoiceCanada #PharmacistsCare #CommunityPharmacy #YourPharmacy #PCH #PCC #LoveMyPharmacy #LocalPharmacy #Pharmacy24
1
Like CommentTo view or add a comment, sign in
-
ALK
50,768 followers
- Report this post
”It’s a big drive for me to pass on my experience to new, young talents – and learn from them in return” 🎤 We have met with colleagues from across our global organisation to get their view on ALK as a workplace. Today we bring a perspective from Michael Jentzsch, who joined the company after finishing his studies as a biologist 26 years ago. Today he works in the commercial part of ALK Germany. Entering ALK as a young scientist, Michael got the opportunity to go to Hørsholm in Denmark to work with the innovative and experienced scientist, Henning Løwenstein, which proved to be important for his decision to stay here for almost three decades: "Henning taught me a lot about allergy research, and working with him truly taught me that ALK is highly scientific and driven by the purpose of helping people with allergy. That really inspired me." Since his entry to the company, Michael has changed the course of his career many times and has gone from scientist over salesman and to his current position in liaison management. He has always seen 'trust' as a keyword for his development opportunities and for ALK in general: "There is a general trust here between colleagues across teams and from leaders to employees. We dare to disagree, and we respect one another for having different viewpoints, areas of expertise and development wishes. And that’s what keeps us innovative," Michael says. He underlines how trust is equally essential for ALK externally, and how the internal culture is important for establishing this trust in our company among healthcare professionals and people living with allergy: "The combination of experienced professionals like myself and new, innovative talents in a trustful culture where we all dare to speak up and change the course if necessary is, in my opinion, what keeps ALK innovative and trustworthy and what keeps our working environment inspirational and pleasant," he says. "At the same time, it is a big drive for me personally to be able to pass on the knowledge from my broad, almost three-decades long experience to young, talented forces while also learning a lot from them in return. I cannot think of a better place to work." If ALK sounds like a workplace for you too, find our current vacant positions at our career site: https://lnkd.in/dUbG_MAr and join us! #allergy #pharma #innovation #professionaldevelopment #career
71
3 Comments
Like CommentTo view or add a comment, sign in
-
Natiiv™
155 followers
- Report this post
🌐 Strategic Milestones Achieved at Tom’s River, New JerseyIn an invigorating series of meetings set against the backdrop of Tom’s River, our discussions with key American investors have marked a significant stride towards Natiiv’s entry into the North American market. Our products, Natiiv Sport Elite and Natiiv Sport Pro, are set to revolutionize the nutraceutical sports drink landscape.The warm hospitality of our hosts at Tom’s River was paralleled only by the promising opportunities laid out during our conversations. As we delved into strategic planning and distribution channels, the setting sun mirrored the bright future we envision.We’re looking forward to forging strong partnerships that are anchored in our shared commitment to health and excellence. Stay connected for further developments as we embark on this exhilarating journey to deliver exceptional nutraceutical products across the continent.#Natiiv #BusinessDevelopment #StrategicPartnerships #Nutraceuticals #MarketExpansion
4
Like CommentTo view or add a comment, sign in
516 followers
- 27 Posts
View Profile
FollowExplore topics
- Sales
- Marketing
- Business Administration
- HR Management
- Content Management
- Engineering
- Soft Skills
- See All